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Abstract 
Heparin-binding EGF-like growth factor (HB-EGF) is a recently identified potent mitogen for smooth muscle cells and fibroblasts. 
HB-EGF has been shown to be an EGF receptor ligand, and also to stimulate pithelial cell growth. A human hepatoma-derived c ll line, 
Mahlavu, was analyzed for the production of HB-EGF mRNA and active HB-EGF protein. It was found that the cell line synthesized very 
low or undetectable basal level of HB-EGF mRNA. However, the addition of 12-O-tetradecanoylphorbol-13-acetate (TPA) led to a rapid 
and transient rise in HB-EGF mRNA level. HB-EGF in Mahlavu cells appears to be regulated by a protein kinase C (PKC) pathway, 
since PKC inhibitors, H7, staurosporin, and calphostin C, abrogated the induction of HB-EGF mRNA by TPA. Unlike vascular smooth 
muscle cells, induction of HB-EGF gene transcription by TPA was blocked completely by incubation with cycloheximide, suggesting that 
protein synthesis may be a prerequisite for HB-EGF gene transcription in Mahlavu cells. Mahlavu cells were also found to release a 
bioactive HB-EGF-like protein into conditioned medium which stimulates DNA synthesis in EP170.7 cells. This activity was neutralized 
by an anti-HB-EGF antibody. These results indicate that HB-EGF gene transcription is regulated via a PKC pathway, resulting in 
secretion of active HB-EGF into the culture medium of hepatoma-derived Mahlavu cells. 
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1. Introduction 
Heparin-binding EGF-like growth factor (HB-EGF) is a 
recently identified 20-22 kDa glycoprotein of a member 
of epidermal growth factor (EGF) family, which was origi- 
nally identified as a secreted growth stimulator for vascu- 
lar smooth muscle cells by macrophages and macrophage- 
like cells [1-4]. HB-EGF is synthesized as a transmem- 
brane precursor protein and processed into a secreted form 
composed of up to 86 amino acids [5]. Secreted HB-EGF 
is significantly bigger than EGF and transforming rowth 
factor-a (TGF-a) and is structurally homologous to them 
[5]. HB-EGF is characterized by a highly hydrophilic 
heparin binding domain at the N-terminal, three disulfide 
loops with spacing characteristic of the EGF family [5], 
and shares about 40% homology with EGF and TGF-a at 
the C-terminal. 
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HB-EGF has been found to be expressed by vascular 
endothelial cells [6] and vascular smooth muscle cells [7], 
and is a component of wound fluid [8]. It has been shown 
that the HB-EGF transcript can be consistently detected in 
a number tissues, particularly lung, skeletal muscle, brain, 
and heart in humans, mice and rats. Relatively low tran- 
script levels have also been detected in the livers of all 
three species [9]. 
It has been shown that EGF and TGF-a stimulate the 
growth of normal hepatocytes [10-13]. It has also been 
shown that TGF-a gene overexpression i  transgenic mice 
induces liver neoplasia, implicating an involvement of 
TGF-a in hepatocarcinogenesis [14,15]. On the other hand, 
we have reported a potent hepatotrophic activity of HB- 
EGF, and expression of HB-EGF mRNA in nonparenchy- 
mal cells [16]. Furthermore, we have recently reported 
overexpression of HB-EGF mRNA and its polypeptide in 
human hepatocellular carcinoma tissue [17]. However, reg- 
ulatory mechanism of HB-EGF production in human hep- 
atoma cells has not been reported. 
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We report here that the basal HB-EGF gene transcrip- 
tion in Mahlavu cells, a human hepatoma cell line, is very 
low, but is induced rapidly and transiently by 12-O-tetra- 
decanoylphorbol-13-acetate (TPA). PKC inhibitors and cy- 
cloheximide abrogated this induction of HB-EGF gene 
transcription by TPA. Therefore, HB-EGF gene transcrip- 
tion may be regulated via a PKC pathway, and protein 
synthesis may be a prerequisite of transcriptional induction 
by TPA in Mahlavu cells. 
2. Materials and methods 
2.1. Chemicals 
12-O-Tetradecanoylphorbol-13-acetate (TPA), stau- 
rosporin, 1,2-dioctanoyl-sn-glycerol (DG), and cyclohex- 
imide were purchased from Sigma Chemicals (St. Louis, 
MO). [3H]Thymidine, [32p]dCTP and a multiprime DNA 
labeling kit were obtained from Amersham Japan, (Tokyo, 
Japan). 1-(5-Isoquinolinesulfonyl)2-2-methylpiperazine di- 
hydrochloride (H7), and calphostin C [18], protein kinase 
C inhibitors, were obtained from Seikagaku Kougyo Cor- 
poration (Tokyo, Japan), and BIOMOL Research Labora- 
tories (PA, USA), respectively. 
2.2. Cell culture 
Mahlavu cells [19] were cultured in Eagle's MEM 
(EMEM) with 10% FCS. For the analysis of HB-EGF gene 
expression, cells were seeded at a cell density of 2 X 105 
cells/ml in 10-cm dishes and allowed to grow for 48 h in 
the presence of 10% FCS. Cells were washed with phos- 
phate-buffered saline (PBS) three times, and the medium 
was changed to serum-free Cosmedium (Cosmo Bio., 
Tokyo, Japan) [20] containing variable doses of TPA. 
Following incubation for a variable number of hours, total 
RNA was isolated and subjected to Northern blot analysis. 
In order to investigate the effects of PKC inhibitors and 
cycloheximide on HB-EGF gene expression, cells were 
exposed to these substances under serum-free conditions 
for 2 h prior to incubation with TPA. 
labeled human HB-EGF cDNA fragment spanning a por- 
tion of the coding and 3'-untranslated region [9] at 42°C. 
The membrane was washed twice with 2 × SSC and 0.1% 
SDS at room temperature, and twice with 0.1 × SSC and 
0.1% SDS at 65°C for 15 min. Finally, the membrane was 
air-dried and exposed to a Kodak XAR film at -70°C. 
2.4. Heparin affinity chromatography 
TSK-heparin 5PW columns (8 X 7.5 mm, Toso, Japan) 
were equilibrated with 0.01 M Tris-HC1, 0.02 M NaC1 (pH 
7.4). Conditioned media were chromatographed on these 
columns by means of a fast-protein liquid chromatography 
(FPLC) system (Pharmacia LKB, Uppsala, Sweden). The 
columns were washed with 20 ml equilibration buffer, and 
bound protein was eluted with a 40-ml linear gradient of 
0.2 M to 2 M NaC1 in 0.01 M Tris-HC1 (pH 7.4) at a flow 
rate of 1 ml/min. One millilitre fractions were collected, 
and a 10-/xl aliquot from each fraction was tested for 
mitogenic activity on EP170.7 cells (a generous gift from 
Dr. Jackie Pierce, NIH, Bethesda) [22] as described below. 
2.5. Growth factor assay 
Growth factor activity was monitored by measuring 
[3H]thymidine incorporation into the DNA of exponen- 
tially growing EP170.7 cells. Cells were grown in RPMI 
1640 medium supplemented with 15% FCS, 5% inter- 
leukin-3 (IL-3) containing medium [23], and penicillin 
(100 U/ml)/streptomycin (100 /zU/ml). After washing 
with RPMI 1640, EP 170.7 cells were plated at a density 
of 2 X 10 4 cells/well in 96-well plates. Appropriate FPLC 
column fraction aliquots were added in a total volume of 
200 /~1. Thirty-six hours later, 1 /xCi of [3H]thymidine 
was added in a volume of 10 /zl PBS. The cells were 
harvested after 4 h and the incorporated [3H]thymidine 
counts were determined by the 1205 Betaplate system 
(Pharmacia LKB). Recombinant HB-EGF protein (Scios 
Nova, Mountain View, CA) was used as a standard to 
estimate the HB-EGF protein content in samples. 
2.6. Neutralization of  growth factor activity 
2.3. Northern blot analysis 
Total RNA was isolated from cells according to the 
method of Chomczynski and Sacchi [21]. Twenty micro- 
gram of total RNA was fractionated on 1% agarose/for- 
maldehyde gel in 1 X MOPS (3-[N-morpholino]propan- 
esulfonic acid) buffer, and then transferred to a nylon 
membrane. The membrane was baked for 2 h at 80°C, and 
prehybridized in a solution of 50% formamide, 5 X SSPE 
(0.75 M NaC1, 25 mM NaHPO 4, 5 mM EDTA, pH 7.4), 
0.5% (w/v)  sodium dodecylsulfate (SDS), 5 x Denhardt's 
solution and 100 /zg/ml salmon sperm DNA at 42°C. The 
membrane was hybridized overnight with a [32p]dCTP- 
An anti-human HB-EGF neutralizing polyclonal anti- 
body (no. 197) was directed against a 75-amino acid form 
of recombinant human HB-EGF and raised in goats by Dr. 
Deborah Damm (Scios Nova). The antibody (no. 197) 
specifically neutralizes human HB-EGF, but not human 
EGF, TGF-c~, amphiregulin or /3-cellulin [24]. In order to 
neutralize HB-EGF obtained from Mahlavu cell-condi- 
tioned media, appropriate amounts of anti-HB-EGF anti- 
body no. 197, and 10 ml of fraction 22 in Fig. 4A 
(mitogenic activity peak) were added directly to an EP 170.7 
cell plate. Incorporation of [3H]thymidine into DNA was 
measured as described above. Normal goat IgG was used 
in control incubations. 
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3. Results TPA (10 ng/ml)  " - I -  "~" "~- - I -  
3.1. Induction of HB-EGF mRNA by TPA in Mahlavu cells H7(501xM)  - - -~-  - - 
Northern blot analysis hows a very low or undetectable 
level of HB-EGF transcripts; however, incubation of 
Mahlavu cells with the tumor promoter TPA resulted in a 
drastic increase in HB-EGF signal that are approx. 2.5 kb, 
similar to the major HB-EGF message xpressed in cul- 
tured human macrophages and U-937 cells (Fig. 1A). This 
induction was transient, occurring within 2 h following 
initiation of TPA exposure, retuming to basal levels at 6 h 
(Fig. 1B). 
3.2. TPA-Induced HB-EGF gene expression was abrogated 
by protein kinase inhibitors 
s taurospor in  (50nM)  - - - 4"  - 
ca lphost in  C (0.5 txM) . . . .  "l" 
HB-EGF - -  
Fig. 2. Effect of protein kinase inhibitors on TPA-induced HB-EGF gene 
expression in Mahlavu cells. Cells were exposed to H7 (50 mM), or 
staurosporin (50 nM) or calphostin C (0.5/~M) for 2 h prior to incubation 
with TPA (10 ng/ml).  As to calphostin C, cells were incubated with this 
agent under ordinary fluorescent lighting. 
Since TPA is known to activate protein kinase C (PKC), 
it was reasonable to speculate that HB-EGF mRNA induc- 
tion by TPA might be regulated via a PKC pathway. DG, a 
A 
11 2 3 4 5 
HB-EGF- -  - -2 .5  kb 
potent activator of PKC, also stimulated HB-EGF gene 
expression (Fig. 1C). Then, the effect of staurosporin (a 
general protein kinase inhibitor) and H7 and calphostin C
(PKC inhibitors) on TPA-induced HB-EGF gene expres- 
sion was investigated. As shown in Fig. 2, 50 nM stau- 
rosporin, 50 /xM H7 or 0.5 /~M calphostin C completely 
inhibited TPA-induced HB-EGF gene expression. These 
results suggest hat PKC might be involved in the mecha- 
nism of HB-EGF mRNA induction by TPA. 
3.3. Effect of cycloheximide on HB-EGF mRNA induction 
by TPA 
13-actin-- 
B 
HB-EGF- -  
TPA (100 ng/ml )  
0 t 2 3 6 12 (hr) 
C 
(snu) 
+ 
~ G F  "- 
Fig. 1. Induction of HB-EGF gene expression by TPA in Mahlavu cells. 
A: HB-EGF mRNA in Mahlavu cells incubated with incremental doses of 
TPA for 3 hr under serum-free conditions. Lane 1: without addition of 
TPA; and lanes 2, 3, 4, and 5: incubated with 1, 10, 100, and 1000 ng/ml  
of TPA, respectively. Rehybridi;mtion with fl-actin cDNA [31] repre- 
sented an internal standard. B: HB-EGF mRNA in Mahlavu cells incu- 
bated with 100 ng/ml  TPA up to 12 h. C, HB-EGF mRNA in Mahlavu 
cells incubated with 5 /zM DG for 3 h. 
HB-EGF mRNA level is induced in smooth muscle 
cells within 1 h following exposure to TPA [6]. In contrast, 
HB-EGF mRNA induction by TPA was not seen within 1 
h following TPA exposure in Mahlavu cells, suggesting 
that the mechanism of HB-EGF gene induction by TPA in 
Mahlavu cells might be different han in smooth muscle 
cells, and that PKC might not be the primary regulatory 
pathway. An inhibitor of protein synthesis, cycloheximide, 
inhibited HB-EGF mRNA induction by TPA (Fig. 3). 
These results indicate that some protein synthesis might be 
required for the induction of HB-EGF gene transcription i
Mahlavu cells. 
TPA (10 ng/ml)  - - 4" 4 -  
CHx (10 p.g/ml) " -i- - 4" 
HB-EGF - -  
Fig. 3. Effect of cyclohexirnide on TPA-induced HB-EGF gene expres- 
sion in Mahlavu cells. Cells were exposed to cycloheximide for 2 h prior 
to incubation with TPA (10 ng/ml).  
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Mahlavu cell-derived presumed HB-EGF was eluted from 
a TSK-heparin column with 1.0 M to 1.2 M NaC1 (Fig. 
4A). Anti-HB-EGF antibody no. 197 was then added prior 
to the EPI70.7 cell assay. We found that the EP170.7 cell 
mitogenic activity was neutralized by anti-HB-EGF anti- 
body in a dose-dependent manner. Ten micrograms per 
millilitre of the antibodies inhibited approx. 80% of the 
mitogenic activity (Fig. 4B). These results demonstrate 
that Mahlavu cells release an active form of HB-EGF 
protein into their culture media in the presence of TPA. 
4. Discussion 
120 
o 100 
g 
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~ 60" 
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normal rabbit IgG n 4. ~ Jr" 
antI-HB-EGF antibody -t- - -  -}- - -  
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Fig. 4. HB-EGF activity in conditioned media from Mahlavu cell cul- 
tures. A: Conditioned media from Mahlavu cell cultures were incubated 
with or without TPA (10 ng/ml) for 24 h, and subjected to a TSK-heparin 
5PW affinity column. HB-EGF activity in the conditioned medium was 
determined as described in Section 2. B: HB-EGF activity of fraction 22 
from A was neutralized by an anti-human HB-EGF polyclonal antibody 
in a dose-dependent manner, as assayed by mitogenic activity for EP170.7 
cells. Values are expressed as mean_+S.E, of triplicate experimental 
samples. 
3.4. Identification of Mahlavu cell-derived HB-EGF in the 
conditioned medium 
Although HB-EGF mRNA was readily detectable in 
Mahlavu cells, it was important to demonstrate hat these 
cells also produce HB-EGF protein, since it is known that 
growth factor mRNA is not always translated into protein 
in some cells [25]. HB-EGF-like protein in Mahlavu cell- 
derived conditioned media was assessed by a combination 
of TSK-heparin affinity chromatography and an EP170.7 
cell assay. HB-EGF-Iike activity (identified by increased 
DNA synthesis in EP170.7 cells) was undetectable in 
conditioned medium from Mahlavu cells not exposed to 
TPA (Fig. 4A). Although incubation with TPA for 6 h was 
not enough to elevate HB-EGF-like activity to be a de- 
tectable level (data not shown), detectable HB-EGF-Iike 
activity accumulated in conditioned medium after 24 h. 
HB-EGF, a member of the epidermal growth factor 
(EGF) family, is a potent mitogen for fibroblasts, smooth 
muscle cells [1], and epithelial cells including keratino- 
cytes and hepatocytes [16]. HB-EGF appears to act on 
target cells through EGF receptor, and may play a role in 
the regulation of epithelial cell growth. Recently, we have 
reported overexpression of HB-EGF mRNA and its 
polypeptide in human hepatocellular carcinoma tissue, im- 
plicating an involvement of HB-EGF in hepatocarcinogen- 
esis [17]. However, the regulatory mechanism of HB-EGF 
production has not been investigated in human hepatoma 
cells. 
Mahlavu cells express a very low or undetectable vel 
of HB-EGF mRNA, but HB-EGF transcripts in this cell 
line are increased significantly by a tumor promoter, TPA. 
Staurosporin and H7, as well as a PKC specific inhibitor 
calphostin C, inhibited HB-EGF mRNA induction by TPA, 
strongly suggesting that PKC activation may play a central 
role in the induction of HB-EGF gene expression in 
Mahlavu cells. 
Induction of HB-EGF gene expression has been re- 
ported recently in vascular endothelial cells by TNF-c~ or 
IL-t/3 [6], rat aortic smooth muscle cells by TPA or 
angiotensin II [7], and in fetal human vascular smooth 
muscle cells by serum, TPA or smooth muscle growth 
factors including PDGF, bFGF and HB-EGF [23]. HB-EGF 
gene expression in the above-mentioned cells is character- 
istic of early response genes such as nuclear transcription 
factors, cytoskeletal nd extracellular matrix proteins, and 
secreted cytokines [26]. 
The regulatory mechanism of HB-EGF gene expression 
in Mahlavu cells seems to be different than in smooth 
muscle cells [23], since (1) the mRNA levels did not 
increase until after the first hour, (2) mRNA induction was 
more pronounced and transient, and (3) cycloheximide 
abrogated HB-EGF mRNA induction in Mahlavu cells. It 
was therefore possible that earlier molecular events pre- 
ceded TPA-related induction of HB-EGF gene expression. 
We have found that Mahlavu cells also secretes biologi- 
cally active HB-EGF protein. Since the presence of HB- 
EGF mRNA is not always associated with HB-EGF pro- 
tein synthesis, and HB-EGF has alternative forms includ- 
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ing a soluble form (mature form) and a transmembrane 
form (precursor form), it was also important o analyze 
HB-EGF protein. Mature HB-EGF protein, consisting of 
up to 86 amino acids [5], is processed from a 208-amino 
acid precursor by cleavage at the transmembrane site [5]. 
The transmembrane form of HB-EGF is also the receptor 
for diphtheria toxin, and expression of HB-EGF precur- 
sor/diphther ia toxin receptor therefore makes cells highly 
sensitive to this toxin [27]. Since processing of TGF-a  is 
induced by TPA [28,29], enhanced processing of HB-EGF 
precursor might occur by TPA via a similar processing 
mechanism. In fact, treatment of a human breast carcinoma 
cell l ine synthesizing mostly transmembrane form of HB- 
EGF with phorbol ester resulted in loss of cell surface 
HB-EGF, lack of sensitivity to diphtheria toxin, and accu- 
mulation of mature HB-EGF in condit ioned medium [30]. 
On this basis, our results show that mature HB-EGF 
elevated in the conditioned medium after HB-EGF gene 
activation by TPA treatrnent may be responsible, in part, 
for the acceleration of the processing enzyme activities by 
TPA. Furthermore, this processing modulated by TPA may 
be an alternative regulatory mechanism for the HB-EGF 
molecule secretion, acting in autocrine, paracrine, and 
juxtacrine manners. 
In conclusion, we have shown that HB-EGF gene ex- 
pression may be regulated via a PKC pathway, resulting in 
secretion of active HB-EGF into the culture medium of 
hepatoma-derived Mahlavu cells. 
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